Biocartis – Sepsis Development Program

Biocartis aims to improve healthcare outcomes by enabling the practice of personalised medicine anywhere, anytime. Biocartis’ ambition is to establish a new gold standard in diagnostic testing and develops assays which have high clinical utility and compelling health economic value. Biocartis’ broad platform capabilities are well suited to address the growing need for individualised and primary care diagnosis. It is a rapidly growing company; to date staff includes over 180 people. Biocartis SA is based at the EPFL’s Innovation Square in Lausanne, Switzerland; the Belgian entity which counts over 100 staff, is located in Mechelen.Biocartis a.o. aims at the development of an integrated sample preparation platform (Polaris) for enabling molecular diagnosis starting from complex clinical samples such as large volumes of blood.

Involved researcher:

B. van Meerbergen, PhD – Polaris (renamed Idylla).
Program Manager at Biocartis. Former position included Senior Scientist at Philips Research and Marie Curie Post-doc at Philips Research.